NO If YES: rewritten closing sentence: N/A Comparison of alternatives Choosing a non-prescription solution for GLP-1 weight management entails balancing features like accessibility, integrated monitoring, and clinician-led care plans
Losing weight can reduce these risks and improve overall health
Your prescriber can work with you to find the optimal balance between therapeutic benefit and tolerability, ensuring that your weight management journey is both effective and sustainable
Tirzepatide patients lost an average of 1.1% more lean body mass after three months and 2% after 12 months of continuous use, the analysis by Massachusetts-based data analytics firm nference found
Statements estimating treatment duration and the number of treatments required are based on the typical experience of our patients
Multiple clinical trials funded by Eli Lilly show Zepbound can reduce the risk of heart attack, stroke, or death in adults with Type 2 diabetes and those with overweight or obesity